What is Aptevo Therapeutics's market cap?

Aptevo Therapeutics (APVO) has a market capitalization of $5.2M and trades on NASDAQ.

Who are Aptevo Therapeutics's competitors?

Aptevo Therapeutics's key competitors include Bristol Myers Squibb, Gilead Sciences Inc., Macrogenics, Inc., and others. These companies compete in similar markets and product categories.

Who does Aptevo Therapeutics partner with?

Aptevo Therapeutics's notable partners include Alligator Bioscience AB, Lonza Group AG, Open Monoclonal Technology, Inc..

What subsidiaries does Aptevo Therapeutics have?

Aptevo Therapeutics's subsidiaries include Aptevo Research and Development LLC.

Where is Aptevo Therapeutics headquartered?

Aptevo Therapeutics is headquartered in United States of America and employs approximately 40 people. It has been publicly traded since 2016.

Aptevo Therapeutics

APVO

Aptevo Therapeutics is a clinical-stage biotechnology company specializing in the development of novel immunotherapy candidates for cancer treatment.

Market cap

$5.25M-99.3%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$6.41Miss by $0.81

Read the full report

Next report

Aug 10, 2026 (In 1 week)

EPS estimate-$6.02

Competitors

By market cap

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

Roivant Sciences$25.0B+224%

Xencor$1.5B+129%

CytomX Therapeutics$707.5M+87.9%

Prelude Therapeutics$309.8M+544%

MacroGenics$254.3M+141%

Aptevo Therapeutics$5.2M-99.3%

By revenue growth

Gilead Sciences+3.5%

Bristol-Myers Squibb+1.8%

Xencor-23.5%

Roivant Sciences-71.6%

CytomX Therapeutics-75.9%

By net margin

Gilead Sciences30.99%+10.2pp

Bristol-Myers Squibb15.01%+3.8pp

CytomX Therapeutics-166.4%-195pp

Xencor-177.1%-13.9pp

Roivant Sciences-6,079.94%—

Profile

Aptevo Therapeutics is a clinical-stage biotechnology company specializing in the development of novel immunotherapy candidates for cancer treatment. The company leverages its proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms to design precision immune-modulatory drugs, including bispecific and multi-specific antibodies. Its core value proposition lies in engineering therapies that enhance the human immune system's ability to target tumor cells while maintaining a differentiated safety profile.

Competitive position

Aptevo is a specialized player in the bispecific antibody space, utilizing proprietary platforms to compete with major pharmaceutical firms by focusing on differentiated safety profiles and modular drug design.

GeographiesUnited States

Customer segmentsPharmaceutical Companies, Biotechnology Companies

Business modelResearch and Development, Licensing and Royalties, Collaborative Partnerships

SuppliersContract manufacturing organizations, Specialized cell line providers, Academic research institutions, Clinical trial site operators

CustomersLarge pharmaceutical companies, Biotechnology firms, Oncology patients

CountryUnited States of America

Listed2016

Employees40.0

CEOJeffrey G. Lamothe

SectorHealthcare

IndustryBiotechnology

Websiteaptevotherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is Aptevo Therapeutics's market cap?: Aptevo Therapeutics (APVO) has a market capitalization of $5.2M and trades on NASDAQ.
Who are Aptevo Therapeutics's competitors?: Aptevo Therapeutics's key competitors include Bristol Myers Squibb, Gilead Sciences Inc., Macrogenics, Inc., and others. These companies compete in similar markets and product categories.
Who does Aptevo Therapeutics partner with?: Aptevo Therapeutics's notable partners include Alligator Bioscience AB, Lonza Group AG, Open Monoclonal Technology, Inc..
What subsidiaries does Aptevo Therapeutics have?: Aptevo Therapeutics's subsidiaries include Aptevo Research and Development LLC.
Where is Aptevo Therapeutics headquartered?: Aptevo Therapeutics is headquartered in United States of America and employs approximately 40 people. It has been publicly traded since 2016.